Cellares Secures $257M Series D to Scale Automated Cell Therapy Manufacturing
Event summary
- $257M Series D led by BlackRock and Eclipse, total capital raised hits $612M.
- Funding to expand automated IDMO Smart Factories in US, Europe, Japan for commercial-scale manufacturing.
- Cell Shuttle™ platform received FDA Advanced Manufacturing Technology (AMT) designation.
- $380M global manufacturing agreement with Bristol Myers Squibb for US, Europe, and Japan capacity.
- Commercial-scale manufacturing expected to begin in 2027.
The big picture
Cellares' massive Series D funding underscores the growing demand for automated, scalable solutions in cell therapy manufacturing. The industry is shifting from artisanal processes to high-tech industrialization, with Cellares positioning itself as a category-defining platform. The $380M Bristol Myers Squibb deal highlights the strategic importance of Cellares' technology in enabling global commercial-scale production.
What we're watching
- Execution Risk
- Whether Cellares can deliver on its ambitious global expansion timeline and meet commercial-scale manufacturing targets by 2027.
- Regulatory Dynamics
- How the FDA's AMT designation will impact Cellares' ability to expedite regulatory approvals for cell therapy products.
- Market Penetration
- The pace at which Cellares can convert its manufacturing agreements with partners like Bristol Myers Squibb into revenue-generating operations.
Related topics